HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target

Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc.

BOLT

0.00

HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ: BOLT) with a Buy and maintains $7 price target.